Invention Grant
US08163281B2 Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
有权
通过靶向CD24-HMGB1-Siglec10轴治疗药物相关的副作用和组织损伤
- Patent Title: Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
- Patent Title (中): 通过靶向CD24-HMGB1-Siglec10轴治疗药物相关的副作用和组织损伤
-
Application No.: US12716842Application Date: 2010-03-03
-
Publication No.: US08163281B2Publication Date: 2012-04-24
- Inventor: Yang Liu , Pan Zheng , Guo-Yun Chen , Xincheng Zheng , Xi Chen , Steve Kunkel
- Applicant: Yang Liu , Pan Zheng , Guo-Yun Chen , Xincheng Zheng , Xi Chen , Steve Kunkel
- Applicant Address: US MI Ann Arbor
- Assignee: The Regents Of The University Of Michigan
- Current Assignee: The Regents Of The University Of Michigan
- Current Assignee Address: US MI Ann Arbor
- Agency: Harness, Dickey & Pierce, P.L.C.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; A61K38/16
Abstract:
The present technology provides methods and compositions for the treatment of tissue-damage related immune dysregulation by administering a composition comprising one or more of CD24; CD24 fragments, variants and derivatives, CD24Fc fusion proteins; HMBG1-binding proteins, binding proteins to HMBG1 Box B; antagonists of HMGB1, polyclonal, monoclonal, recombinant, chimeric, humanized scFv antibodies and antibody fragments to HMGB1 or fragments of HMGB1 and antibodies that bind and suppress the activity of HMGB1 Box B; Siglec 10 agonists such as anti-Siglec 10 antibodies; and combinations thereof to a patient.
Public/Granted literature
- US20110064746A1 TREATMENT OF DRUG-RELATED SIDE EFFECT AND TISSUE DAMAGE BY TARGETING THE CD24-HMGB1-SIGLEC10 AXIS Public/Granted day:2011-03-17
Information query
